Zacks: Brokerages Expect Intellia Therapeutics Inc (NASDAQ:NTLA) to Announce -$0.61 Earnings Per Share

Wall Street analysts expect Intellia Therapeutics Inc (NASDAQ:NTLA) to post earnings of ($0.61) per share for the current quarter, Zacks reports. Five analysts have made estimates for Intellia Therapeutics’ earnings. The highest EPS estimate is ($0.47) and the lowest is ($0.79). Intellia Therapeutics reported earnings of ($0.52) per share during the same quarter last year, which would indicate a negative year-over-year growth rate of 17.3%. The firm is expected to report its next earnings results on Wednesday, August 7th.

On average, analysts expect that Intellia Therapeutics will report full year earnings of ($2.40) per share for the current financial year, with EPS estimates ranging from ($3.08) to ($1.90). For the next fiscal year, analysts forecast that the business will post earnings of ($2.86) per share, with EPS estimates ranging from ($3.75) to ($2.12). Zacks Investment Research’s EPS averages are a mean average based on a survey of research firms that cover Intellia Therapeutics.

Intellia Therapeutics (NASDAQ:NTLA) last posted its earnings results on Thursday, May 2nd. The company reported ($0.49) EPS for the quarter, topping analysts’ consensus estimates of ($0.53) by $0.04. The company had revenue of $10.43 million for the quarter, compared to the consensus estimate of $9.43 million. Intellia Therapeutics had a negative return on equity of 31.68% and a negative net margin of 257.28%. The firm’s revenue for the quarter was up 39.7% on a year-over-year basis. During the same period in the previous year, the business earned ($0.51) earnings per share.

A number of equities research analysts have issued reports on NTLA shares. Wedbush restated an “outperform” rating on shares of Idera Pharmaceuticals in a research report on Friday, May 3rd. Roth Capital started coverage on Crispr Therapeutics in a research report on Monday, June 10th. They set a “buy” rating and a $50.00 price objective on the stock. Evercore ISI started coverage on Homology Medicines in a research report on Thursday, April 11th. They set an “outperform” rating and a $29.00 price objective on the stock. BidaskClub upgraded Zynerba Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, June 20th. Finally, Robert W. Baird started coverage on Intellia Therapeutics in a research report on Monday, July 8th. They set an “outperform” rating and a $23.00 price objective on the stock. Eight research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average target price of $25.31.

Hedge funds and other institutional investors have recently modified their holdings of the company. Tortoise Investment Management LLC raised its holdings in shares of Intellia Therapeutics by 100.0% in the first quarter. Tortoise Investment Management LLC now owns 2,000 shares of the company’s stock worth $34,000 after buying an additional 1,000 shares during the period. Quantamental Technologies LLC raised its holdings in shares of Intellia Therapeutics by 1,170.4% in the first quarter. Quantamental Technologies LLC now owns 3,303 shares of the company’s stock worth $56,000 after buying an additional 3,043 shares during the period. Resources Investment Advisors Inc. purchased a new stake in shares of Intellia Therapeutics in the first quarter worth approximately $92,000. NumerixS Investment Technologies Inc purchased a new stake in shares of Intellia Therapeutics in the first quarter worth approximately $110,000. Finally, BNP Paribas Arbitrage SA raised its holdings in shares of Intellia Therapeutics by 942.0% in the first quarter. BNP Paribas Arbitrage SA now owns 7,648 shares of the company’s stock worth $131,000 after buying an additional 6,914 shares during the period. Hedge funds and other institutional investors own 74.34% of the company’s stock.

NTLA stock traded down $0.11 during midday trading on Tuesday, reaching $17.10. 397,369 shares of the company traded hands, compared to its average volume of 798,326. Intellia Therapeutics has a 52-week low of $11.03 and a 52-week high of $32.95. The company has a quick ratio of 7.74, a current ratio of 7.74 and a debt-to-equity ratio of 0.06. The stock’s 50 day simple moving average is $15.32. The firm has a market cap of $781.66 million, a price-to-earnings ratio of -8.64 and a beta of 2.62.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, and primary hyperoxaluria.

Featured Story: Trading signals using Bollinger bands

Get a free copy of the Zacks research report on Intellia Therapeutics (NTLA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Intellia Therapeutics (NASDAQ:NTLA)

Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.